WO2025062372 - TYK2 INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
National phase entry:
Publication Number
WO/2025/062372
Publication Date
27.03.2025
International Application No.
PCT/IB2024/059183
International Filing Date
20.09.2024
Title **
[English]
TYK2 INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
[French]
INHIBITEURS DE TYK2 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE MALADIE INFLAMMATOIRE DE L'INTESTIN
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
SINGH, Namita
HARBISON, Carole Elizabeth
DURAIRAJ, Chandra
NGUYEN, Van Anh
HEAP, Graham Alastair Richard
XIA, Guliang
Priority Data
63/584,324
21.09.2023
US
63/551,960
09.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3424 | |
| EPO | Filing, Examination, Granting | 23814 | |
| Japan | Filing, Examination, Granting | 2980 | |
| South Korea | Filing, Examination, Granting | 3690 | |
| USA | Filing, Examination, Granting | 11190 |
Total:
45,098
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compounds, compositions thereof, and methods of using the same in dosing protocols for the inhibition of TYK2, and the treatment of inflammatory disorders including inflammatory bowel disease, including Crohn's disease or ulcerative colitis are described.[French]
L'invention concerne des composés, des compositions de ceux-ci et des méthodes d'utilisation de ceux-ci dans des protocoles de dosage pour l'inhibition de TYK2, et le traitement de troubles inflammatoires comprenant une maladie intestinale inflammatoire, y compris la maladie de Crohn ou la rectocolite hémorragique.